Department of Biomedical and Biotechnological Sciences, section of Microbiology, University of Catania, Italy.
Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Diagn Microbiol Infect Dis. 2019 Dec;95(4):114884. doi: 10.1016/j.diagmicrobio.2019.114884. Epub 2019 Aug 7.
The purpose of the present study was to investigate the in vitro activity of ceftobiprole in combination with other antimicrobials against 27 selected Gram-negative isolates, including ESBL-producing E. coli and KPC-OXA-48-producing K. pneumoniae. Ceftobiprole activity in combination with amikacin, colistin, levofloxacin, piperacillin/tazobactam and rifampin was evaluated by time-kill curves and gradient-cross method (except colistin). Among the 27 strains tested with gradient strips most were resistant to ceftobiprole. Synergy was observed in some cases with piperacillin/tazobactam. There was at least one synergistic combination towards 9 isolates belonging to different species. No antagonism was observed with any of the antibiotic tested. In time-kill curves, performed for 12 selected isolates, synergistic interaction was more frequent, occurring with 32/60 combinations. The most interesting results of our study are the bactericidal effects of ceftobiprole in combination with colistin or piperacillin/tazobactam tested against Gram-negative isolates, including KPC and OXA-48-producing K. pneumoniae.
本研究旨在研究头孢洛林与其他抗菌药物联合应用对 27 株选定的革兰氏阴性菌(包括产 ESBL 的大肠埃希菌和产 KPC-OXA-48 的肺炎克雷伯菌)的体外活性。通过时间杀伤曲线和梯度交叉法(不包括多粘菌素)评估头孢洛林与阿米卡星、多粘菌素、左氧氟沙星、哌拉西林/他唑巴坦和利福平联合的活性。在使用梯度条测试的 27 株菌株中,大多数对头孢洛林耐药。在某些情况下与哌拉西林/他唑巴坦观察到协同作用。对于属于不同种的 9 株菌,至少有一个协同组合。用任何测试的抗生素都没有观察到拮抗作用。在为 12 株选定的分离株进行的时间杀伤曲线中,协同相互作用更为频繁,发生了 32/60 种组合。我们研究的最有趣的结果是头孢洛林与多粘菌素或哌拉西林/他唑巴坦联合使用对包括产 KPC 和 OXA-48 的肺炎克雷伯菌在内的革兰氏阴性菌的杀菌作用。